Cybin (CYBN) announced that the United States Patent and Trademark Office has granted U.S. patent 12,318,477 in support of its CYB004 deuterated DMT program in development for the treatment of generalized anxiety disorder. The patent, which is expected to provide exclusivity until 2040, includes claims to novel formulations of DMT and deuterated isotopologues for intramuscular injection, including CYB004.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYBN:
- Cybin CEO to Discuss Strategic Advances at Upcoming Fireside Chat
- Cybin Supports FDA’s Push for Psychedelic Research
- VA secretary wants to find answers on psychedelics therapies, Politico says
- Psychedelic: Atai, Enveric, Incannex and Relmada report quarterly results
- Cybin Partners with Thermo Fisher for U.S. Manufacturing of CYB003